ERBB2 and neoplasm: The results of the current study revealedthat RIT with [225Ac]Ac-DOTA-trastuzumab F(ab')2 and [225Ac]Ac-DOTA-trastuzumab Fab eliminatedhematologicaltoxicity (Figure 5)and further, these RICs significantly inhibited tumor growth in NRGmice with s.c. HER2-positive 164/8-1B/H2N.luc+ human BCtumors.